News

This study used biological indicators containing Geobacillus stearothermophilus spores and a new technology to continuously monitor incubated BIs and record nonsterile results.

A comprehensive book about mass transfer benefits from the author's personal touch.

The authors describe the implementation of an on-line particle-size analyzer on an active pharmaceutical ingredient milling operation at a commercial site.

BioNanomatrix (Philadelphia) names Edward Erickson president and CEO; and More.

Hospira, a specialty pharmaceutical company, has agreed to acquire Orchid Chemicals' Pharmaceuticals for $400 million.

Merck & Co. Acquires Avecia Biologics; Ambrilia Biopharma Closes Manufacturing Facility; And More.

Fraud and abuse in healthcare costs individual governments as much as $23 billion a year, according to estimates from the World Health Organization (WHO).

The European Public Health Alliance published its comments about the Falsified Medicines Directive currently under debate by the European Parliament and Council.

Mergers and acquisitions will contribute almost two-thirds of peer-set sales growth until 2014, according to market analyst Datamonitor.

Eli Lilly outlined its growth strategy at its annual meeting with the investment community last week.

Also, Abbott to acquire Starlims Technologies; GSK Biologicals to form alliance with Intercell.

PharmTech's monthly newsletter, Equipment & Processing Report, reviews the Editor's Picks for the December 2009 edition from Sepha and AdvantaPure.

Do advanced therapies represent medical miracles or risky business? This is the question that is debated by an Informa analyst in an Executive Briefing for Scrip.

The European Medicines Agency unveiled several changes to the organization, including a new structure and visual identity.

Company and People Notes: Also, Pfizer and Protalix enter agreement; Watson acquires Arrow Group; and more.

The US Congressional Budget Office released a report that analyzes the pharmaceutical industry?s advertising strategies.

Personalized medicine has been described by analysts PricewaterhouseCoopers as a "disruptive influence" that will create both opportunities and challenges for traditional healthcare.

The private industry has been urged to join a public sector commitment fund in the UK to advance manufacturing R&D in bioprocessing, following the investment of approximately £9 million from two UK research councils.

European business leaders are missing opportunities to reduce their environmental footprint and drive efficiencies through document governance, according to research from Ricoh, an electronic solutions provider.

sanofi-aventis (Paris) announced last week that it has signed a memorandum of understanding (MoU)with Prominvest.

Novartis officially inaugurated its large-scale flu cell-culture vaccine and adjuvant manufacturing facility in Holly Springs, North Carolina.

The US Pharmacopeial Convention posted a proposed revised standard for what should and should not appear on the ferrules and cap overseals of medication vials.

Also, Merck & Co. extends collaboration with Idera Pharmaceuticals; Pfizer establishes R&D center in China; more...

Also, new European Generic medicines Association president begins term.

Pharmaceutical Technology talks to FDA's Justina A. Molzon about current discussions with international regulators, and how, after 20 years of harmonization activities and the common technical document, ICH has benefited regulatory authorities.

Guidance has been published in the United Kingdom regarding a new European variations regulation that comes into effect on Jan. 1, 2010.

Readers can learn about the importance of measuring and controlling water activity in a comprehensive new book.

Polymorph screening is a critical step in developing an active pharmaceutical ingredient for a pharmaceutical formulation.

The authors describe the development and organization of the Product Quality Research Institute and highlight some of the important projects conducted by its Working Groups.

An agreement between sanofi-aventis and the Medicines for Malaria Venture (MMV) has lead to the initiation of the largest safety and efficacy study of an antimalarial drug.